ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Phase 2
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: YM178
Drug: Placebo
First Posted Date
2007-09-10
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
842
Registration Number
NCT00527033

Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients

Phase 3
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: tacrolimus ointment
First Posted Date
2007-09-03
Last Posted Date
2014-09-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
303
Registration Number
NCT00523952

AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: AGS-1C4D4
First Posted Date
2007-08-22
Last Posted Date
2014-05-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
13
Registration Number
NCT00519233

Phase 1 Study of OSI-930 in Cancer Patients

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: OSI-930
First Posted Date
2007-08-09
Last Posted Date
2011-09-27
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
60
Registration Number
NCT00513851
Locations
🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

🇬🇧

Cancer Research UK Professor of Medical Oncology, Sutton, Surrey, United Kingdom

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Continuous OSI-906 Dosing

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: OSI-906
First Posted Date
2007-08-09
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
95
Registration Number
NCT00514007
Locations
🇬🇧

The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

🇺🇸

Vanderbilt Universtiy Medical Center, Nashville, Tennessee, United States

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

First Posted Date
2007-08-09
Last Posted Date
2015-08-13
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
32
Registration Number
NCT00514267

Study of Intermittent OSI-906 Dosing

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: OSI-906
First Posted Date
2007-08-09
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
79
Registration Number
NCT00514306
Locations
🇬🇧

Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

Phase 4
Completed
Conditions
Graft Rejection
Kidney Transplantation
First Posted Date
2007-08-02
Last Posted Date
2007-08-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
450
Registration Number
NCT00510913

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH

First Posted Date
2007-08-02
Last Posted Date
2014-08-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
919
Registration Number
NCT00510406

ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

Phase 2
Terminated
Conditions
Diabetic Neuropathies
Interventions
Drug: ASP8825
Drug: Placebo
First Posted Date
2007-07-30
Last Posted Date
2008-12-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
199
Registration Number
NCT00508430
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy